ArriVent BioPharma (NASDAQ:AVBP) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of ArriVent BioPharma (NASDAQ:AVBP) in a research report report published on Tuesday morning, Marketbeat.com reports. The firm issued a buy rating and a $25.00 price objective on the stock. HC Wainwright also issued estimates for ArriVent BioPharma’s Q1 2024 earnings at ($1.25) EPS, Q2 2024 earnings at ($0.64) EPS, Q3 2024 earnings at ($0.67) EPS, Q4 2024 earnings at ($0.70) EPS, FY2024 earnings at ($3.03) EPS, Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.82) EPS and FY2025 earnings at ($3.09) EPS.

Other research analysts have also recently issued research reports about the company. The Goldman Sachs Group started coverage on ArriVent BioPharma in a research note on Tuesday, February 20th. They issued a buy rating and a $27.00 price target on the stock. Jefferies Financial Group began coverage on ArriVent BioPharma in a research note on Tuesday, February 20th. They set a buy rating and a $35.00 target price for the company. Finally, Citigroup started coverage on shares of ArriVent BioPharma in a research note on Tuesday, February 20th. They issued a buy rating and a $30.00 price target for the company.

ArriVent BioPharma Trading Up 2.6 %

Shares of AVBP stock opened at $17.23 on Tuesday. The business has a fifty day moving average price of $18.02. ArriVent BioPharma has a 12 month low of $14.35 and a 12 month high of $25.95.

Institutional Trading of ArriVent BioPharma

An institutional investor recently bought a new position in ArriVent BioPharma stock. BNP Paribas Financial Markets purchased a new stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) in the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 4,659 shares of the company’s stock, valued at approximately $83,000. Institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.